{"id":6573,"date":"2022-10-21T08:00:00","date_gmt":"2022-10-21T08:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/"},"modified":"2022-10-21T08:00:00","modified_gmt":"2022-10-21T08:00:00","slug":"nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/","title":{"rendered":"Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB (publ) meddelar idag att bolaget har tecknat ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med ett l\u00e4kemedelsbolag f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system, PharmaShell\u00ae, i en dep\u00e5formulering av ett specifikt l\u00e4kemedel f\u00f6r intravitreal administrering.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Studien avser en specifik kommersiell l\u00e4kemedelsprodukt i syfte att med hj\u00e4lp av PharmaShell-systemet ta fram en l\u00e5ngtidsverkande injicerbar produkt f\u00f6r intravitreal<strong> <\/strong>administrering.<\/p>\n<p>\u201dDet \u00e4r v\u00e4ldigt intressant att vi i detta projekt nyttjar v\u00e5rt PharmaShell-system f\u00f6r intravitreal administrering, d\u00e4r den h\u00f6ga andelen l\u00e4kemedelsubstans (drug load) som vi kan \u00e5stadkomma \u00e4r en verklig nyckelf\u00f6rdel. En lokal och riktad fris\u00e4ttning av den aktiva substansen i \u00f6gat kan inneb\u00e4ra flera f\u00f6rdelar. Det \u00e4r ocks\u00e5 mycket sp\u00e4nnande f\u00f6r Nanexa att inleda ett samarbete med detta l\u00e4kemedelsbolag inom \u00f6gonomr\u00e5det och vi ser fram emot att p\u00e5b\u00f6rja arbetet inom kort, med m\u00e5let att generera resultat som kan ligga till grund f\u00f6r ett mer omfattande utvecklingsprogram och l\u00e5ngsiktigt licensavtal\u201d, s\u00e4ger David Westberg, VD f\u00f6r Nanexa.<\/p>\n<p>Avtalet reglerar bland annat detaljer kring vad som ska unders\u00f6kas, klarg\u00f6rande kring patentr\u00e4ttigheter, samt en fastst\u00e4lld ers\u00e4ttning till Nanexa f\u00f6r denna utv\u00e4rdering.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/483be21b-1ded-43ac-98b3-e718f388e86c\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB (publ) meddelar idag att bolaget har tecknat ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med ett l\u00e4kemedelsbolag f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system, PharmaShell\u00ae, i en dep\u00e5formulering av ett specifikt l\u00e4kemedel f\u00f6r intravitreal administrering.<\/p>\n","protected":false},"template":"","class_list":["post-6573","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att bolaget har tecknat ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med ett l\u00e4kemedelsbolag f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system, PharmaShell\u00ae, i en dep\u00e5formulering av ett specifikt l\u00e4kemedel f\u00f6r intravitreal administrering.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\\\/\",\"name\":\"Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-10-21T08:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att bolaget har tecknat ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med ett l\u00e4kemedelsbolag f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system, PharmaShell\u00ae, i en dep\u00e5formulering av ett specifikt l\u00e4kemedel f\u00f6r intravitreal administrering.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/","name":"Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-10-21T08:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-utvarderingsavtal-med-lakemedelsbolag-specialiserat-inom-ogonomradet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa tecknar utv\u00e4rderingsavtal med l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}